GlobeNewswire Clinical StudiesOriginal article
Spherix Global Insights Finds One-Third of Treated MASH Patients Remain Inadequately Controlled Even as Prescription Use Expands
Data ReadoutMixedNegative
AI Analysis
Summary
Spherix Global Insights research indicates that one-third of treated MASH patients remain inadequately controlled, with physicians expressing preference for longer trials and combination therapy approaches as new treatment options enter the market.
Outcome Details
One-third of treated MASH patients remain inadequately controlled despite expanding prescription use
Importance:4/10
Sentiment:
-0.30
MASHmarket_researchtreatment_efficacyphysician_insightscombination_therapy
Read the original article
Published by GlobeNewswire Clinical Studies on August 20, 2026 3:04 PM